Imunon, Inc.
Close on Oct 19, 2026
- Market cap
- $4.95M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $-0.84 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-1.16 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | $-2.15 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | – | $-0.28 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-0.34 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | $-0.51 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | Before market open | – | – | – |
Press releases
Announcements Imunon filed with the SEC
Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Announces Up to $10 Million Cash Financing
Material agreement · New financial obligation · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Announces Stock Dividend Boosting Shareholder Value
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
Other events · EX-99.1 to Form 8-K
Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase
Results of operations · EX-99.1 to Form 8-K
Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Appoints Director Dr. Stacy R. Lindborg as President and CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
Reports 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Chairman to lead day-to-day operations, active search underway for CEO successor.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Reports 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
stand by. Good morning. My name is Marlise and I will be your operator today. At this time, I would like to welcome you to IMUNON’s
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Celsion Corporation Reports First Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Material agreement · Other events · EX-99.1 to Form 8-K
Corporation Reports 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K